Background: CHOP is currently considered the gold standard of treatment for intermediate grade lymphomas. We designed a new regimen known as 'ATT' (alternating triple therapy) which uses three non-cross resistant combinations in alternating sequence for nine cycles.
Introduction
The most common histologic type of lymphoma is diffuse large cell (DLCL). This sub-type constitutes approximately 70% of all intermediate and high grade lymphomas. The introduction of the CHOP regimen in the 1970s represented a major advance in the management of these disorders. With this regimen, approximately 30%-40% of patients with advanced DLCL can be cured. The third generation regimens such as MACOP-B, m-BACOD, and ProMACE-CytaBOM were recently compared against CHOP in a randomized study conducted by the Southwest Oncology Group [1] . The results of that trial showed that there was no survival or FFS advantage with any of the third generation regimens as compared to CHOP. Because CHOP is less expensive and less toxic, it is considered to be the treatment of choice for these disorders. Although CHOP can be considered the standard therapy for DLCL, there is a clear need for a better regimen that can improve the outcome in certain unfavorable prognostic groups.
Several studies of prognostic factors in DLCL have shown differences in survival according to tumor burden, LDH, cytogenetic abnormalities, molecular genetic abnormalities, adhesion molecules, immunophenotype and serum cytokine levels [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . In 1988 we devised a system to classify patients according to prognostic risk [14] . This system, known as the M.D. Anderson staging system considers LDH and tumor burden as the two variables and divides cases into stage A, B, C and D, the latter being the worst and A being the best. Tumor burden was defined on the basis of number of extranodal sites as well as bulkiness. Thus a patient with low tumor burden (no bulky sites, < 2 extranodal sites, absence of simultaneous para-aortic/pelvic adenopathy) and low LDH would be classified as MD Anderson stage A while anyone with high tumor burden (at least two of the following features: a bulky site, >2 extranodal sites or simultaneous para-aortic/pelvic adenopathy) plus high LDH would be considered stage D. This system has been validated in a subsequent prospective clinical trial and also independently by Coiffieret al. [8] . d Each adverse variable is assigned one point. One point is assigned for each bulky mass. The sum total of all points is considered as the tumor score. b Cases with extranodal head and neck presentations, not measurable bidimensionally, will be analyzed by TNM system using T3-T4 as bulky. Other extranodal presentations such as gastric, kidney, liver, etc., if not measurable, will be considered bulky if they infiltrate ^2 / 3 of that organ.
In 1988 we developed a new regimen known as the ATT (alternating triple therapy) protocol which uses three non-cross resistant combinations given in alternating sequence for a total of nine cycles. The three combinations include a CHOP-like regimen as well as MINE and ASHAP. The MINE and ara-C-platinum (ASHAP) regimen were derived from our salvage experience in which we have shown that MINE and an ara-C-platinum regimen are non-cross resistant [15] . The rationale of the multi-regimen approach used in the ATT study is based on the Goldie-Coldman hypothesis which postulates the previously existing presence of tumor cells resistant to a given chemotherapy agent is a function of tumor size [16] . Thus, the use of three alternating noncross resistant regimens should in theory overcome this problem to some extent. The M.D. Anderson staging system was used to determine eligibility for the ATT trial. Only cases of M.D. Anderson stage B, C and D were entered on this study. Subsequent to the above staging system, two new simplified and hence more convenient predictive systems, known as the international index [17] and the tumor score system [18] (Table 1) have been devised. We have used the tumor score system to analyze the results of the ATT clinical trial. An analysis of the ATT protocol revealed certain differences in survival and failurefree survival (FFS) which couldn't have been as clearly appreciated if the analysis had disregarded the existence of prognostic categories.
Materials and methods

ATT regimen
Eligibility criteria
All previously untreated patients with large cell lymphoma (either diffuse or follicular) and immunoblastic lymphoma with M.D. Anderson Cancer Center stages B. C or D were eligible. The M.D. Anderson stages were based on the assessment of tumor burden and serum LDH levels as previously published [14] . Patients had to sign a consent form approved by the Institutional Review Board and had to be at least 16 years old. There was no upper age limit. Adequate bone marrow and liver function were required (absolute neutrophil count > 1,000. platelet count 3= 100,000 and bilirubin ^1.5 mg%) unless due to bone marrow or liver involvement by lymphoma. Patients with serum creatinine elevations thought to be due to renal involvement by lymphoma or secondary to hydronephrosis were eligible but were first treated with m-BACOS without the methotrexate; once a response was obtained and the serum creatinine normalized they were given ASHAP. Anyone with renal failure unrelated to lymphoma was considered ineligible for study. Patients with brain or meningeal involvement were eligible. Patients with proven HIV infection or unwilling to accept transfusions of blood products were excluded from the study.
Drugs and doses
The ATT regimen consisted of three different non-cross resistant combinations given in alternating fashion for a total of nine courses. The doses and schedule are listed in Table 2 . Patients older than 65 were not given bleomycin and received the first dose of chemotherapy in the hospital. Hydration in the hospital consisted of 250 cc/hour of normal saline with 50 gm of mannitol, 15 meq of KG and 6 meq of MgSO 4 added to each liter of fluid starting six hours before the platinum and continued during the platinum infusion. All others were treated in the out-patient clinic using portable out-patient continuous infusion pumps. In the out-patient setting, hydration was carried out by delivering 1000 cc of the same solution described above but given over three to four hours preceding the platinum chemotherapy and administered once daily for the duration of platinum treatment. Electrolytes, calcium and magnesium levels were carefully followed during the administration of ASHAP and the fluid balance was also checked daily. Frequently it was necessary to administer furosemide 20-40 mg i.v. for fluid retention. A central catheter was required to administer the intravenous continuous infusion therapy.
Dose adjustments
Doses were adjusted according to myelosuppression. Growth factors were not employed in this trial. In essence, anyone with a nadir neutrophil count of <200 or platelet count < 20,000 or documented infection related to neutropenia, had a 20% reduction of the myelosuppressive agents during the subsequent courses. Myelosuppressive agents were considered all except steroids, vincristine, bleomycin, platinum and methotrexate with leucovorin. Those patients who sustained a serum creatinine elevation ranging from 1.5-2.0 mg % received a 25% reduction in the platinum doses. Those with creatinine 10 mg/m" 240 mg/m 2 elevations of 2.1-2.5 mg% had a 50% reduction and those with > 2.5 mg% had the platinum containing ASHAP regimen deleted during subsequent courses.
Evaluation of response to treatment
Follow-up studies consisted of physical examination and history, routine blood tests, and radiographic studies of initial areas of disease, all repeated after every cycle of treatment (CT scans were done every three cycles). After therapy, these studies were performed at fourmonth intervals for the first two years, at six-month intervals during the third year, and yearly thereafter.
Complete remission (CR) was defined as the disappearance of all signs and symptoms of disease as determined by clinical, radiographic, and laboratory parameters. Patients who responded to treatment and had residual radiographic abnormalities (usually less than 20% of the original mass) that remained unchanged for longer than six months after therapy was discontinued were considered to be in CR. There were 37 cases which met the latter criteria of which 19 (51%) remain in remission. Partial remission (PR) was defined as a reduction of 50% or more in measurable disease for at least one month. Any other responses, including mixed response, stable disease, progressive disease, early death, or death from toxicity were considered treatment failures.
Statistical analysis
The objective of this study was to compare the therapeutic efficacy of ATTand CHOP/CMED [19] in intermediate grade lymphomas. This is a historical controlled study comparing the results of two separate phase II clinical trials. All analyses have been performed on the basis of patient evaluability.
The outcome measurements for this trial were: tumor related mortality, gross survival and failure free survival (FFS). For FFS an event was defined as any patient who relapsed or died of toxicity. For analysis of tumor-related mortality, an event was defined as any death which occurred in a patient who had previously relapsed or any treatment-related death. For gross survival, any death irrespective of the cause was considered as an event. Ten out 268 (3.7%) of evaluable patients dying of causes unrelated to the disease or therapy were censored in the ATT group and four of 108 (3.7%) in the CHOP/ CMED group.
Tumor related mortality and FFS were initially analyzed using the method of Kaplan-Meier [20] . A stepwise Cox proportional hazard model was performed to determine if previously reported risk factors were related to survival or FFS. Variables used in the analyses included type of treatment, tumor score and age. The interaction of variables with treatment group was included if significant at the 0.05 level. The Wald test statistic was used to test significance of variables. The hazard ratio of an outcome (survival, FFS) as adjusted for significant variables (P = 0.05) was calculated using the parameter estimates from the final Cox proportion hazard model. The hazard ratio is defined as the ratio of risk of outcome for the ATT relative to CHOP/CMED treatment groups. Statistical analyses were performed using the SAS software.
Results
A total of 292 patients with intermediate grade lymphoma or immunoblastic lymphoma were entered on study. Patients with mantle cell lymphoma are not included. There were 23 ineligible cases: six because of incorrect diagnosis, three due to HIV positivity, four due to a second simultaneous life-threatening malignancy, seven because they presented with M.D. Anderson stage A, one because of a low platelet count related to alcoholism, one because of prior radiotherapy and one because she refused blood products due to religious convictions. In addition there was one inevaluable case, a patient who withdrew his consent after entry into study but before receiving any therapy. Thus, a total of 268 patients with intermediate grade or immunoblastic lymphoma were evaluable. The characteristics of the evaluable patient population are described in Table 3 . The only statistically significant difference between these two groups is in the higher frequency of T-cell lymphomas in the CHOP/CMED study. Since the entity now known as 'T-cell rich B-cell lymphoma' [21] was not recognized during the time period in which the CHOP/CMED trial was conducted, it is very likely that such cases were called T-cell lymphomas in that study while on the ATT trial they were classified as B-cell DLCL. The response rate of the 268 evaluable patients treated with the ATT regimen includes 79.1% complete remissions, 18.3% partial responses and 2.6% failures.
The response rate according to prognostic factors is shown in Table 4 . Serum (3-2 microglobulin, LDH and tumor score system (which includes both serum (3-2-microglobulin and LDH) were the factors more significantly associated with CR rate.
Analysis of survival
The median follow-up of surviving patients is 32 months (range 17-71 months). We examined the tumor-related mortality of the 268 patients treated with ATT and compared it with those treated with CHOP/CMED. The latter regimen consists of CHOP alternating with CMED (cyclophosphamide, high dose methotrexate, etoposide and dexamethasone) and has been shown in the past to be equivalent or slightly better than CHOP-Bleo [19] . For the comparison between ATT and CHOP/CMED only those patients who had an MD Anderson stage B, In five cases (3-2 microglobulin level was not available to calculate the exact tumor score but the latter was at least 3, which is the cut-off for poor prognosis.
IBL -Immunoblastic lymphoma. c Of the 15 T-cell lymphomas, four were K.i-1 anaplastic large-cell and 11 were of peripheral T-cell type, not otherwise specified.
C or D were included since those with M.D. Anderson stage A were not entered on the ATT trial. There were 108 cases treated with CHOP/CMED with stage B, C or D. Although the 40 months tumor related survival was 64% for patients treated with ATT in contrast to 58% for CHOP/CMED, this difference was not statistically significant (P -0.1). The corresponding 40 months gross survival was 61% for ATT vs. 55% for CHOP/CMED (/» = 0.19).
Using the tumor score system, we then examined the mortality of patients treated with ATT vs. CHOP/CMED separating them into two groups, one with favorable and one with unfavorable tumor scores. Although no statistically significant difference was found for those with favorable scores (40 months tumor related survival: 78% CHOP/CMED vs. 76% ATT), there was a significant difference in favor of ATT for those with unfavorable tumor scores (Figure 1 ). There was no significant difference for gross survival (which includes all deaths irre- spective of cause) between the ATT and CHOP/CMED groups with favorable scores (78% CHOP/CMED vs. 73% ATT) while for the unfavorable group it was 28% for CHOP/CMED and 52% for ATT, P = 0.004. In view of the controversy about the clinical behavior of patients with follicular large cell lymphoma, we then removed these cases from the analysis but the same results were observed. When we examined the prognostic factors associated with tumor related mortality in the ATT group, the Cox proportional hazard model identified tumor score and age as significant. When treatment category was included in the model, there was no statistically significant difference between the ATT and CHOP/CMED groups. The hazard ratio for ATT was 0.78 (95% confidence interval (95% CI): 0.55-1.11).
Analysis of failure free survival
We then proceeded to compare the FFS results with the ATT and CHOP/CMED regimens using the tumor score system. While there was a superior outcome for those with favorable scores (tumor score 0-2) treated with CHOP/CMED (Table 5), the opposite was true for patients treated with ATT who presented with unfavorable tumor scores of > 3 ( Figure 2) .
The Cox proportional hazard model identified tumor score, age and the interaction between treatment and tumor score as statistically significant. There was a statistically significant difference between the treatment groups. Patients with high tumor score receiving ATT had better FFS than those who received CHOP/CMED; the estimated hazard ratio comparing treatment group ATT vs. CHOP/CMED was 0.65 (95% CI: 0.45-0.95), indicating that patients treated with ATT had a longer FFS as those treated with CHOP/CMED. Patients with low tumor score receiving CHOP/CMED had better FFS than those receiving ATT. The estimated hazard ratio was 2.02 (95% CI: 1.00-4.09) indicating that patients treated with ATT had half the FFS than those treated with CHOP/CMED. Removal of patients with follicular largecell lymphoma did not in any way affect the outcome. In order to determine if the FFS difference in favor of CHOP/CMED in the group with low tumor scores could be explained on the basis of a higher lethal toxicity rate in the more intensive ATT regimen, we examined this in both treatment groups. The lethal toxicity rate on ATT was 3/112 (2.7%) vs. 0/52 for CHOP/CMED. This indicates that toxicity can not be the explanation for the superior FFS in the CHOP/CMED group.
The favorable trend for the FFS of patients treated with CHOP/CMED whose tumor score <3 would suggest that their survival should also be better than for ATT yet no significant difference in the survival between ATT and CHOP/CMED was observed. This raises the question as to the possibility that more succesful salvage treatment for those who failed on ATT might explain the lack of difference in their survival. There are 11 patients on the ATT regimen who have relapsed but have not died. Seven of these relapsed with a low grade lymphoma in spite of the fact that they had an initial diagnosis of large cell lymphoma. Of the remaining four patients, two have undergone a bone marrow transplant and are in a second CR while the other two are still alive with disease. In contrast only two of the patients who relapsed on CHOP/CMED are currently alive; one of them was salvaged with high-dose chemotherapy and bone marrow transplant and the other one with standard dose salvage chemotherapy.
Effect of age and tumor score on outcome
Because of the more intensive and potentially more toxic nature of the ATT regimen particularly in elderly patients, we examined the association of age with outcome. The FFS was analyzed for those > 60 years old vs. those < 61 years old. The results show that age > 60 was associated with a statistically significant higher failure rate. At three years, the FFS for patients under 61 years old treated with ATT was 61% vs. 47% for those over 60 years old (P = 0.005).
We then examined the outcome of patients ^ 60 years old with a tumor score ^ 3 and related it to the treat- ment regimen used. We found a highly significant difference in favor of the ATT regimen for patients ^ 60 y/o ( Figure 3 , Table 5 ). We then examined the FFS of those younger than 61 years old with favorable (0-2) tumor scores and found no significant difference between ATT and CHOP/CMED (Table 5 ). There was no significant difference observed between CHOP/CMED and ATT for patients > 60 years old in the unfavorable tumor score category of 5= 3 suggesting that older patients did not benefit from the more intensive ATT regimen (Table 5) . On the other hand, in those with a favorable tumor score older than 60 years a significant difference in favor of CHOP/CMED was observed ( Table 5) . The difference in outcome between young vs. older patients in the ATT protocol was in part due to an increased rate of lethal toxicity in patients over 60 years old compared to those younger than 61. In the ATT regimen there were 10/107 cases of toxic deaths (9.3%) in the older than 60 category contrasted to three of 154 (1.9%, P -0.007) in younger patients. The CHOP/ CMED regimen was associated with a lower lethal toxicity rate (two of 108 = 1.9%). Both toxic deaths in the CHOP/CMED regimen occurred in patients older than 60 years.
In order to determine if the higher lethal toxicity rate of ATT in older patients was the sole cause for the difference in FFS between those over 60 and those younger than 60, we excluded from the analysis those patients who died of toxicity. In spite of this, there was still a significant difference in FFS in favor of younger patients (at three years, 51% FFS for those > 60 vs. 61% for those > = 0.04).
Discussion
General
Prognostic factors are known to correlate well with outcome in patients with lymphoma. Patients who have favorable prognostic features have fared well with standard CHOP-like regimens while others have done poorly with this treatment. For this reason we have chosen to prospectively apply prognostic factors to select the treatment and to develop new therapeutic strategies for the management of patients with lymphoma. In the current study we selected patients with at least one adverse prognostic factor using a staging system devised several years ago at M.D. Anderson Cancer Center [14] . Hence this study does not address those patients with the most favorable prognosis, those with intermediate grade M.D.
Anderson stage A who constitute 20% of the patients seen in our institution.
Analysis of survival
In 1992 we introduced a new predictive system, the 'tumor score' which is based on five variables: serum (3-2 microglobulin, LDH, Ann Arbor stage, constitutional symptoms and bulky disease [18] . This system, which was derived from 144 patients treated with CHOP/ CMED, divides patients into two major categories assigning each patient one point for each adverse variable present: those with a score of 0-2 whose prognosis is favorable, and those with a score of ^ 3 whose prognosis is unfavorable. From the comparison of CHOP/CMED and ATT, it would appear at first glance that there is no significant difference in survival between these two regimens. However, upon further analysis, the survival of those with a tumor score ^ 3 treated with ATT was found to be better when compared with equivalent cases treated with CHOP/CMED (Figure 1 ). There was no significant difference in survival between ATT and CHOP/CMED when those with a tumor score 0-2 were analyzed separately (Table 5) . Thus it appears that the ATT regimen has a positive impact on survival in the setting of adverse prognostic factors, but not in those patients with favorable features.
Analysis of failure free survival
In parallel with the tumor mortality, the FFS was also better for patients with tumor scores 5= 3 when treated with ATT. However, this advantage appears to be limited fundamentally to patients younger than 61 years (Figure 3) . On the other hand, patients with favorable tumor scores did not fare better when treated with ATT, irrespective of age (Table 5 ). This was most evident in patients over 61 years with tumor score <3, where CHOP/CMED was associated with a statistically superior outcome (Table 5) . When tested by multivariate analysis, ATT and young age were selected as independent variables associated with a favorable outcome.
The fact that the FFS was superior for the CHOP/ CMED regimen in cases with a favorable tumor score while the opposite was true for those with an unfavorable tumor score is an intriguing finding. Similarly intriguing results have been published in multiple myeloma where treatment with a simple combination of melphalan-prednisolone was better than an intensive combination regimen for patients with favorable prognostic features but a more intensive combination chemotherapy strategy was superior for those with poor prognosis [22] . Also a recent study comparing high-dose chemotherapy plus autologous bone marrow transplantation for slow responders with intermediate grade lymphoma showed that the group treated with highdose chemotherapy actually showed a trend for a worse outcome compared with those randomized to standard CHOP therapy [23] . The difference was not due to an increase in lethal toxicity so that other explanations are more likely. Furthermore, in a recently published randomized study, Mayer et al. described a superior outcome for patients with acute myeloblastic leukemia who received high-dose ara-C as consolidation after achieving complete remission. This superior outcome, however, was observed only in those patients younger than 61 years [24] .
Four possible hypotheses could explain the superiority of CHOP/CMED in cases with favorable tumor scores: 1) the more intensive ATT regimen is associated with a higher rate of lethal toxicity in patients with good prognosis; 2) the myelosuppressive as well as the nonmyelosuppressive toxicity of ATT in older patients is excessive and could lead to a compromise of the dose intensity as compared to the less toxic CHOP/CMED regimen; 3) the intensive ATT regimen is associated with excessive suppression of the host defense system which probably plays a critical role in eradicating minimal residual disease after treatment is completed. This could result in a higher relapse rate in patients whose prognosis is already favorable and in whom more intensive therapy is not only unnecessary but perhaps even counterproductive; 4) the results could be spurious and a prospective randomized study might be necessary for a legitimate comparison of the two regimens.
In regards to the first hypothesis, we have observed that the lethal toxicity of ATT is higher than that of CHOP/CMED in patients with favorable tumor scores (2.7% vs. 0%) but even after eliminating from the analysis those cases who died of toxic causes, the FFS of those with a favorable tumor score is still superior for CHOP/CMED. Hence, this first possibility is part of the explanation but not the major reason for the inferior performance of ATT in cases with favorable tumor scores.
In order to address the second hypothesis, we determined whether older patients received the same or a lower dose intensity than those younger than 61. We thus calculated the dose intensity for the first three courses of chemotherapy. The median dose intensity after the first three courses for patients older than 60 was 76% as contrasted with 82% for those younger than 61 (P < 0.001). However when we tested the correlation of dose intensity with FFS and tumor mortality we did not observe any significant difference between those receiving > 80% vs. < 81% or > 70% vs. < 71% intensity after three courses. This suggests that a reduced dose intensity is unlikely to be the explanation for the poor performance of ATT in elderly patients. Furthermore, younger patients receiving > 80% dose intensity still had a better outcome than older patients receiving the same dose intensity. Although this analysis of dose intensity is retrospective in nature, the lack of any significant influence of a lower dose intensity on prognosis is surprising. Retrospective studies of dose intensity have concluded the opposite: that a lower dose intensity is associated with a poor outcome. Nevertheless, our study suggests the opposite conclusion: a lower dose intensity in this study did not lead to a worse outcome. This finding can not be totally explained either by the retrospective nature of the study or by prognostic factors.
Regarding the third hypothesis, there is abundant clinical evidence that points out that the immune system is important in lymphomagenesis. Patients with an immunocompromised state have a higher incidence of lymphoma compared to the general population [25] . Moreover, the lack of expression of MHC molecules on the surface of lymphoma cells has been associated with an adverse clinical outcome after therapy for diffuse large cell lymphoma, thus suggesting the critical role of host defense in this group of disorders [26, 27] . Finally, it has been clearly shown that in young patients, following intensive chemotherapy, efficient T-cell regenerattion occurs in relation to thymic activity and consequently immunorestoration is better achieved in younger patients [28] . In older adults, polyclonal expansion of post-thymicT cells can contribute to T-cell reconstitution but in this setting T-cell recovery is incomplete [28] . In view of this evidence which underlines the important role of the immune system, we tend to favor the third hypothesis.
In conclusion, an interesting interaction between age and tumor score with FFS was observed ( Table 5 ). In patients younger than 61 with unfavorable tumor scores, there was a highly significant difference in the FFS in favor of ATT while in those older than 60 with favorable tumor scores there was a significant difference in favor of CHOP/CMED ( Figure 3 , Table 5 ). In those younger than 61 with favorable tumor scores this difference was less pronounced and not statistically significant (Table 5) . Finally, in those older than 60 with unfavorable tumor scores there was no significant advantage for ATT (Table 5) . Thus, it appears that the ATT regimen is not appropriate treatment for patients older than 60, independent of whether the tumor score is favorable or unfavorable and it does not appear to be indicated either for young patients with favorable tumor scores. In view of the phase II nature of this study, the above conclusions have to be considered as hypotheses to be tested in a prospective trial.
In summary, it appears that ATT is a superior regimen for young patients with poor prognostic features while CHOP or CHOP-like regimens might be better for those with good prognosis irrespective of age. On the other hand, those over 60 years with unfavorable tumor scores have fared poorly irrespective of treatment regimen used and for these patients new investigational studies are recommendable. In order to confirm the findings of this phase II study, a phase III trial is desirable.
